---
schema_version: "secwatch.filing_event.v1"
accession: "0000318154-25-000005"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2025-02-04T23:59:59+00:00"
generated_at: "2026-05-27T03:42:15.808148+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amgen Q4 revenue up 11% to $9.1B; non-GAAP EPS $5.31 (+13%)

## Summary
- Q4 product sales up 11% (14% volume growth); FY product sales up 19% (23% volume growth).
- GAAP EPS $1.16 vs $1.42; FY $7.56 vs $12.49, driven by mark-to-market losses on equity investments.
- Non-GAAP EPS $5.31 vs $4.71; FY $19.84 vs $18.65, driven by higher revenues offset by higher expenses.
- Full-year free cash flow $10.4B vs $7.4B in 2023, driven by business performance and working capital timing.
- 21 products achieved record full-year sales; rare disease sales $1.2B in Q4.

## SEC filing metadata
- accession: 0000318154-25-000005
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2025-02-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000031815425000005/0000318154-25-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000031815425000005/amgn-20250204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000318154-25-000005
- JSON: https://secwatch.observer/filing/0000318154-25-000005.json
- Plain text: https://secwatch.observer/filing/0000318154-25-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.